neridronate neridronic acid Updated Nov 11
Watch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.
- CRPS-1 affects roughly 65,000 newly diagnosed U.S. patients annually with no currently FDA-approved treatment, representing a large unmet need and potential orphan-drug commercial opportunity.
- Neridronate has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, providing regulatory advantages including expedited review and potential market exclusivity.
- The $150 million oversubscribed PIPE is expected to fully fund the company through Phase 3 topline results in 2028 and into the first half of 2029, reducing near-term dilution risk.
- Neridronate is still in Phase 3 with no topline data yet; Phase 3 trials in pain indications have a high historical failure rate.
- Current HOWL shareholders will own only roughly 7% of the combined company post-merger, representing massive dilution for existing holders.
- Analyst coverage is stale (last action December 2025) and the consensus is mixed: 3 hold, 1 sell, 2 strong sell ratings with a mean price target of $7 (though coverageStale flag is true).